Top ▲
This section gives an overview of the disease, and where available shows the following:
More information can be found in the help pages.
✖Disease ID: | 811 | |
Name: | Renal cell carcinoma | |
Associated with: | 3 targets | |
3 immuno-relevant ligands | ![]() |
Database Links |
Disease Ontology:
DOID:4450 |
Click on the target name to link to its detailed view page
Where available, information is display on the role of the target in the disease; drugs which target the disease and their therapeutic use and side-effects.
If there is mutation data curated in GtoPdb this is indicated, with a link back to the appropriate section on the target detailed view page
Immuno ligand interactions - If available, a table of immuno-relevant ligands is shown. These ligands have been curated as having an association to the disease and possess interaction data with the target in GtoPdb. The approval status of the ligand is shown, along with curator comments and an indication of whether the target is considered the primary target of the ligand.
More information can be found in the help pages.
✖FZD8 | |
References: | 6 |
programmed cell death 1 (CD279) | |||||||||||
Comments: | A combination therapy of nivolumab plus ipilimumab was granted FDA approval in April 2018, for the treatment of intermediate or poor risk, previously untreated advanced renal cell carcinoma. | ||||||||||
References: | 3 | ||||||||||
Ligand interactions: |
|
trophoblast glycoprotein | ||||||||||||||||
Role: | Trophoblast glycoprotein 5T4 expression is upregulated in many solid tumour types. The clinical efficacy of targeting 5T4-expressing RCC tumours has been evaluated in Phase 2 clinical trials. | |||||||||||||||
References: | 1,5,12-13 | |||||||||||||||
Ligand interactions: |
|
Click ligand name to view ligand summary page
Click the arrow in the final column to expand comments
More information can be found in the help pages.
✖Key to terms and symbols | Click ligand name to view ligand summary | Click column headers to sort | |||||||||||||||||||||||||||||||||||
|
1. Eisen T, Hedlund G, Forsberg G, Hawkins R. (2014) Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin. Curr Oncol Rep, 16 (2): 370. [PMID:24445502]
2. Elkord E, Burt DJ, Sundstedt A, Nordle Ö, Hedlund G, Hawkins RE. (2015) Immunological response and overall survival in a subset of advanced renal cell carcinoma patients from a randomized phase 2/3 study of naptumomab estafenatox plus IFN-α versus IFN-α. Oncotarget, 6 (6): 4428-39. [PMID:25669986]
3. FDA. FDA approves nivolumab plus ipilimumab combination for intermediate or poor-risk advanced renal cell carcinoma. Accessed on 18/04/2018. Modified on 18/04/2018. www.fda.gov, https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm604685.htm?utm_campaign=Oncology%204%2F16%2F2018&utm_medium=email&utm_source=Eloqua&elqTrackId=461a88586a9a4db284ceb54da34a6a23&elq=8b10e118e0b249beb2807c129fc264e8&elqaid=3169&elqat=1&elqCampaignId=2374
4. FDA. Nivolumab in combination with ipilimumab. Accessed on 17/06/2016. Modified on 17/06/2016. US Food and Drug Administration, http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm465274.htm
5. Hawkins RE, Gore M, Shparyk Y, Bondar V, Gladkov O, Ganev T, Harza M, Polenkov S, Bondarenko I, Karlov P et al.. (2016) A Randomized Phase II/III Study of Naptumomab Estafenatox + IFNα versus IFNα in Renal Cell Carcinoma: Final Analysis with Baseline Biomarker Subgroup and Trend Analysis. Clin Cancer Res, 22 (13): 3172-81. [PMID:26851187]
6. Janssens N, Andries L, Janicot M, Perera T, Bakker A. (2004) Alteration of frizzled expression in renal cell carcinoma. Tumour Biol, 25 (4): 161-71. [PMID:15557753]
7. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P et al.. (2015) Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med, 373 (1): 23-34. [PMID:26027431]
8. Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER et al.. (2015) Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma. N Engl J Med, 373 (19): 1803-13. [PMID:26406148]
9. Motzer RJ, Tannir NM, McDermott DF, Arén Frontera O, Melichar B, Choueiri TK, Plimack ER, Barthélémy P, Porta C, George S et al.. (2018) Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma. N Engl J Med, 378 (14): 1277-1290. [PMID:29562145]
10. O'Sullivan Coyne G, Madan RA, Gulley JL. (2014) Nivolumab: promising survival signal coupled with limited toxicity raises expectations. J Clin Oncol, 32 (10): 986-8. [PMID:24590655]
11. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS et al.. (2015) Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med, 372 (21): 2006-17. [PMID:25891304]
12. Shaw DM, Connolly NB, Patel PM, Kilany S, Hedlund G, Nordle O, Forsberg G, Zweit J, Stern PL, Hawkins RE. (2007) A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma. Br J Cancer, 96 (4): 567-74. [PMID:17285137]
13. Stern PL, Harrop R. (2017) 5T4 oncofoetal antigen: an attractive target for immune intervention in cancer. Cancer Immunol Immunother, 66 (4): 415-426. [PMID:27757559]